Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
7.19
-0.05 (-0.69%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Zevra Therapeutics Revenue
In the year 2024, Zevra Therapeutics had annual revenue of $23.61M, down -14.02%. Zevra Therapeutics had revenue of $12.04M in the quarter ending December 31, 2024, a decrease of -6.79%.
Revenue (ttm)
$23.61M
Revenue Growth
-14.02%
P/S Ratio
14.10
Revenue / Employee
$400,203
Employees
59
Market Cap
389.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
| Dec 31, 2023 | 27.46M | 17.30M | 170.26% |
| Dec 31, 2022 | 10.16M | -18.49M | -64.53% |
| Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
| Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
ZVRA News
- 9 days ago - Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism - GlobeNewsWire
- 19 days ago - Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewsWire
- 25 days ago - Zevra Therapeutics Files Preliminary Proxy - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Zevra Reports Full Year 2024 and Fourth Quarter Financial Results - GlobeNewsWire
- 2 months ago - Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewsWire
- 2 months ago - Zevra to Report 2024 Fourth Quarter and Full Year Financial Results - GlobeNewsWire